Catherine Wu, MD

Dana-Farber Cancer Institute · company speakers →

Dr. Catherine Wu will discuss how multiple lines of evidence have convincingly demonstrated tumor neoantigens as an important class of immunogenic tumor antigens and have motivated the development of personalized cancer neoantigen targeting approaches. Neoantigens arise from amino acid changes encoded by somatic mutations in the tumor cell and have the potential to bind to and be presented by personal human leukocyte antigen molecules. As a field, we have now successfully moved beyond the first wave proof-of-concept studies that have demonstrated the safety, feasibility, and high immunogenicity of these personalized vaccines. An imperative now is to address the challenges of discovering and optimizing the selection of antigens to target, the delivery approach, and extending this promising approach to a broader array of cancer settings.

Is this you? Claim this profile →